PGE2
ApprovedSmall molecule
PGE2 is one of 14 small molecule programs targeting Premature rupture of membranes. It is currently in Approved.
2
Indications
5
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Premature Rupture of Membranes
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Imdur
OOmnivium
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
E-Mycin
AAzurity Pharmaceuticals
Phase 3
Antibiotic
PfizerPhase 3
PGE2
UUnknown Sponsor
Approved
Indocin
LLife Extension Foundation Inc.
Phase 2
Antibiotics Administration
TThe Central and Eastern European Gynecologic Oncology Group
Phase 3
Cervidil
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Induction of Labor2 trials
Combined Foley Catheter Balloon and PGE2 Vaginal Ovule for Induction of Labor at Term: A Randomized Study
Completed·ZZeynep Kamil Maternity and Pediatric Research and Training Hospital·Phase 2·NCT02861079·300 enrolled
Early Amniotomy After Vaginal Prostaglandin E2 for Induction of Labor at Term: a Randomized Clinical Trial
Completed·ZZeynep Kamil Maternity and Pediatric Research and Training Hospital·Phase 2·NCT02856724·200 enrolled
Premature rupture of membranes2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PGE2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUnknown Sponsor